Induction of apoptosis in multiple myeloma cells by a statin-thalidomide combination can be enhanced by p38 MAPK inhibition

Leukemia Research

Volumn 37, Issue 5, 2013, Pages 586-594

  Slawinska Brych, Adrianna ^a   Zdzisinska, Barbara ^a   Mizerska Dudka, Magdalena ^a   Kandefer Szerszen, Martyna ^a  

^a MARIA CURIE SK ODOWSKA UNIVERSITY   (Poland)

Author keywords

MAPK; MMP 9; Multiple myeloma; P38 MAPK inhibitor; Statins; Thalidomide; VEGF

Indexed keywords

CASPASE 3; CASPASE 8; FLUINDOSTATIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; MEVINOLIN; MITOGEN ACTIVATED PROTEIN KINASE P38; SIMVASTATIN; THALIDOMIDE;

ANTIPROLIFERATIVE ACTIVITY; APOPTOSIS; ARTICLE; CANCER INHIBITION; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG EFFECT; DRUG POTENTIATION; ENZYME ACTIVATION; ENZYME INHIBITION; ENZYME PHOSPHORYLATION; HUMAN; HUMAN CELL; MULTIPLE MYELOMA; PRIORITY JOURNAL; UPREGULATION;

APOPTOSIS; CASPASES; CELL LINE, TUMOR; ENZYME ACTIVATION; GENE EXPRESSION REGULATION, LEUKEMIC; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; IMMUNOSUPPRESSIVE AGENTS; MAP KINASE KINASE 4; MULTIPLE MYELOMA; P38 MITOGEN-ACTIVATED PROTEIN KINASES; PHOSPHORYLATION; PROTEIN KINASE INHIBITORS; SIMVASTATIN; THALIDOMIDE; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 84875905277     PISSN: 01452126     EISSN: 18735835     Source Type: Journal    
DOI: 10.1016/j.leukres.2013.01.022     Document Type: Article

References (41)

1. Dalton W.S. Drug resistance and drug development in multiple myeloma. Semin Oncol 2002, 29:21-25.
2. Bladé J., Cibeira M.T., Rosiñol L. Novel drugs for the treatment of multiple myeloma. Haematologica 2010, 95:702-704.
3. Palumbo A., Ambrosini M.T., Benevolo G., Pregno P., Pescosta N., Callea V., et al. Italian multiple myeloma network; Gruppo Italiano Malattie Ematologicche dell'Adulto. Bortezomib, melphalan, prednisone, and thalidomide for relapsed multiple myeloma. Blood 2007, 109:2767-2772.
4. Corso A., Zappasodi P., Barbarano L., Petrucci M.T., Palumbo A., Caravita T., et al. Long-term outcome in relapsed and refractory multiple myeloma treated with thalidomide. Balancing efficacy and side-effects. Leuk Res 2009, 33:e145-e149.
5. Endo A. The discovery and development of HMG-CoA reductase inhibitors. J Lipid Res 1994, 33:1569-1582.
6. Cafforio P., Dammacco F., Gernone A., Silvestris F. Statins activate the mitochondrial pathway of apoptosis in human lymphoblasts and myeloma cells. Carcinogenesis 2005, 26:883-891.
7. Sławińska A., Kandefer-Szerszeń M. The anticancer properties of statins. Postepy Hig Med Dosw 2008, 62:393-404.
8. Tu Y.S., Kang X.L., Zhou J.G., Lv X.F., Tang Y.B., Guan Y.Y. Involvement of Chk1-Cdc25A-cyclin A/CDK2 pathway in simvastatin induced S-phase cell cycle arrest and apoptosis in multiple myeloma cells. Eur J Pharmacol 2011, 670:356-364.
9. Schmidmaier R., Baumann P., Bumeder I., Meinhardt G., Straka C., Emmerich B. First clinical experience with simvastatin to overcome drug resistance in refractory multiple myeloma. Eur J Haematol 2007, 79:240-243.
10. Clendening J.W., Pandyra A., Li Z., Boutros P.C., Martirosyan A., Lehner R., et al. Exploiting the mevalonate pathway to distinguish statin-sensitive multiple myeloma. Blood 2010, 115:4787-4797.
11. D'Amato R.J., Loughnan M.S., Flynn E., Folkman J. Thalidomide is an inhibitor of angiogenesis. Proc Natl Acad Sci USA 1994, 91:4082-4085.
12. Gupta D., Treon S.P., Shima Y., Hideshima T., Podar K., Tai Y.T., et al. Adherence of multiple myeloma cells to bone marrow stromal cells upregulates vascular endothelial growth factor secretion: therapeutic applications. Leukemia 2001, 15:1950-1961.
13. Hideshima T., Chauhan D., Shima Y., Raje N., Davies F.E., Tai Y.T., et al. Thalidomide and its analogs overcome drug resistance of human multiple myeloma cells to conventional therapy. Blood 2000, 96:2943-2950.
14. Corral L.G., Haslett P.A., Muller G.W., Chen R., Wong L.M., Ocampo C.J., et al. Differential cytokine modulation and T cell activation by two distinct classes of thalidomide analogues that are potent inhibitors of TNF-alpha. J Immunol 1999, 163:380-386.
15. + subset. J Exp Med 1998, 187:1885-1892.
16. Davies F.E., Raje N., Hideshima T., Lentzsch S., Young G., Tai Y.T., et al. Thalidomide and immunomodulatory derivatives augment natural killer cell cytotoxicity in multiple myeloma. Blood 2001, 98:210-216.
17. Dmoszynska A., Podhorecka M., Klimek P., Grzasko N. Lovastatin and thalidomide have a combined effect on the rate of multiple myeloma cell apoptosis in short term cell cultures. Eur J Clin Pharmacol 2006, 62:325-329.
18. Holstein S.A., Tong H., Hohl R.J. Differential activities of thalidomide and isoprenoid biosynthetic pathway inhibitors in multiple myeloma cells. Leuk Res 2010, 34:344-351.
19. Hus M., Grzasko N., Szostek M., Pluta A., Helbig G., Woszczyk D., et al. Thalidomide, dexamethasone and lovastatin with autologous stem cell transplantation as a salvage immunomodulatory therapy in patients with relapsed and refractory multiple myeloma. Ann Hematol 2011, 90:1161-1166.
20. van der Spek E., Bloem A.C., Lokhorst H.M., van Kessel B., Bogers-Boer L., van de Donk N.W. Inhibition of the mevalonate pathway potentiates the effects of lenalidomide in myeloma. Leuk Res 2009, 33:100-108.
21. Bommert K., Bargou R.C., Stühmer T. Signalling and survival pathways in multiple myeloma. Eur J Cancer 2006, 42:1574-1580.
22. Hideshima T., Akiyama M., Hayashi T., Richardson P., Schlossman R., Chauhan D., et al. Targeting p38 MAPK inhibits multiple myeloma cell growth in the bone marrow milieu. Blood 2003, 101:703-705.
23. Medicherla S., Reddy M., Ying J., Navas T.A., Li L., Nguyen A.N., et al. p38alpha-selective MAP kinase inhibitor reduces tumor growth in mouse xenograft models of multiple myeloma. Anticancer Res 2008, 28:3827-3833.
24. Wen J., Feng Y., Huang W., Chen H., Liao B., Rice L., et al. Enhanced antimyeloma cytotoxicity by the combination of arsenic trioxide and bortezomib is further potentiated by p38 MAPK inhibition. Leuk Res 2010, 34:85-92.
25. Keyomarsi K., Sandoval L., Band V., Pardee A.B. Synchronization of tumor and normal cells from G1 to multiple cell cycles by lovastatin. Cancer Res 1991, 51:3602-3609.
26. Segarra M., Lozano E., Corbera-Bellalta M., Vilardell C., Cibeira M.T., Esparza J., et al. Thalidomide decreases gelatinase production by malignant B lymphoid cell lines through disruption of multiple integrin-mediated signaling pathways. Haematologica 2010, 95:456-463.
27. Jin Z., El-Deiry W.S. Overview of cell death signaling pathways. Cancer Biol Ther 2005, 4:139-163.
28. Mitsiades N., Mitsiades C.S., Poulaki V., Chauhan D., Richardson P.G., Hideshima T., et al. Apoptotic signaling induced by immunomodulatory thalidomide analogs in human multiple myeloma cells: therapeutic implications. Blood 2002, 99:4525-4530.
29. Chauhan D., Li G., Hideshima T., Podar K., Mitsiades C., Mitsiades N., et al. JNK-dependent release of mitochondrial protein, Smac, during apoptosis in multiple myeloma (MM) cells. J Biol Chem 2003, 278:17593-17596.
30. Stokoe D., Engel K., Campbell D.G., Cohen P., Gaestel M. Identification of MAPKAP kinase 2 as a major enzyme responsible for the phosphorylation of the small mammalian heat shock proteins. FEBS Lett 1992, 313:307-313.
31. New L., Jiang Y., Zhao M., Liu K., Zhu W., Flood L.J., et al. PRAK, a novel protein kinase regulated by the p38 MAP kinase. EMBO J 1998, 17:3372-3384.
32. Concannon C.G., Gorman A.M., Samali A. On the role of Hsp27 in regulating apoptosis. Apoptosis 2003, 8:61-70.
33. Vacca A., Ribatti D., Presta M., Minischetti M., Iurlaro M., Ria R., et al. Bone marrow neovascularization plasma cell angiogenic potential and matrix metalloproteinase-2 secretion parallel progression of human multiple myeloma. Blood 1999, 93:3064-3073.
34. Alexandrakis M.G., Sfiridaki A., Miyakis S., Pappa C., Kandidaki E., Alegakis A., et al. Relationship between serum levels of vascular endothelial growth factor, hepatocyte growth factor and matrix metalloproteinase-9 with biochemical markers of bone disease in multiple myeloma. Clin Chim Acta 2007, 379:31-35.
35. Van de Broek I., Asosingh K., Allegaert V., Leleu X., Facon T., Vanderkerken K., et al. Bone marrow endothelial cells increase the invasiveness of human multiple myeloma cells through upregulation of MMP-9: evidence for a role of hepatocyte growth factor. Leukemia 2004, 18:976-982.
36. Ribatti D., Surico G., Vacca A., De Leonardis F., Lastilla G., Montaldo P.G., et al. Angiogenesis extent and expression of matrix metalloproteinase-2 and -9 correlate with progression in human neuroblastoma. Life Sci 2001, 68:1161-1168.
37. Kurizaki T., Toi M., Tominaga T. Relationship between matrix metalloproteinase expression and tumor angiogenesis in human breast carcinoma. Oncol Rep 1998, 5:673-677.
38. Hill P.A., Docherty A.J.P., Bottemley K.M.K., O'Connell J.P., Morphy R., Raynolds J.J., et al. Inhibition of bone resorption in vitro by selective inhibitors of gelatinase an collagenase. Biochem J 1995, 308:167-174.
39. Engsig M.T., Chen Q.J., Vu T.H., Pedersen A.C., Therkidsen B., Lund L.R., et al. Matrix metalloproteinase 9 and vascular endothelial growth factor are essential for osteoclast recruitment into developing long bones. J Cell Biol 2000, 151:879-889.
40. Thunyakitpisal P.D., Chaisuparat R. Simvastatin, an HMG-CoA reductase inhibitor, reduced the expression of matrix metalloproteinase-9 (gelatinase B) in osteoblastic cells and HT1080 fibrosarcoma cells. J Pharmacol Sci 2004, 94:403-409.
41. Hecht M., Heider U., Kaiser M., von Metzler I., Sterz J., Sezer O. Osteoblasts promote migration and invasion of myeloma cells through upregulation of matrix metalloproteinases, urokinase plasminogen activator, hepatocyte growth factor and activation of p38 MAPK. Br J Haematol 2007, 138:446-458.